No decline in functional status or cognitive function during the first year after treatment initiation for early-stage breast cancer in women aged 75 years and older: a prospective observational matched cohort study
This prospective matched cohort study found that early-stage breast cancer and its treatment did not accelerate functional or cognitive decline in women aged 75 and older during the first year compared to cancer-free peers.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
As people live longer, the question of how to maintain independence and mental sharpness in later life becomes increasingly urgent. Aging naturally brings a gradual slowing of physical abilities and a slight dimming of memory, changes that can make daily tasks harder and reduce quality of life. For women over seventy-five, a diagnosis of breast cancer adds a new layer of complexity. Doctors and families often worry that the treatments required to fight the disease—surgery, radiation, or medication—might accelerate this decline, leaving a patient more frail or confused than the cancer itself would have. The central challenge for geriatric oncology is distinguishing between the inevitable wear and tear of aging and the specific toll of medical intervention. Without this clarity, it is difficult to know whether to treat aggressively or to hold back, and whether the cure might inadvertently harm the patient's ability to live well.
To answer this, researchers in the Netherlands set out to compare two groups of women who were as similar as possible in age and starting health. One group consisted of 168 women aged seventy-five and older who had just been diagnosed with early-stage breast cancer and were beginning their treatment. The other group was a carefully selected set of 336 women of the same age who did not have cancer. The researchers matched these women one-to-two, ensuring that for every woman with cancer, there were two women without cancer who shared her age and her baseline level of physical and mental function. This matching was crucial; it allowed the scientists to see if the cancer group changed differently over time compared to the non-cancer group, effectively isolating the impact of the disease and its treatment from the natural aging process.
The study followed these women for one year after treatment began. The researchers measured functional status using a standard questionnaire that asks about the ability to perform daily activities, such as bathing, dressing, or shopping. They also measured cognitive function using a well-known test that checks for memory, orientation, and basic reasoning skills. In the group receiving treatment, the vast majority had early-stage disease. Most underwent surgery, and about half received radiation or hormone-blocking medication. Notably, chemotherapy was almost never used in this group, with fewer than one percent of patients receiving it. This reflects a common clinical approach for very elderly patients, where the risks of aggressive chemotherapy often outweigh the benefits.
Over the course of the year, the researchers tracked how the scores for both groups changed. They found that the women with breast cancer did not experience a faster or steeper drop in their physical or mental abilities compared to the women without cancer. In fact, the data showed a very slight, statistically significant improvement in functional status for the cancer group, suggesting that after the initial recovery from surgery, these women were managing their daily lives just as well as their peers. Similarly, their cognitive scores remained stable, showing no signs of accelerated decline. The women without cancer, who served as the control group, showed the same patterns of stability or slight improvement. The study explicitly noted that the control group actually had more chronic health conditions, such as heart disease or arthritis, yet they still performed just as well as the cancer patients.
These findings suggest that for relatively fit older women with early-stage breast cancer, the standard treatments of surgery, radiation, and hormone therapy do not necessarily trigger a rapid loss of independence or mental clarity in the first year. The results challenge the assumption that cancer treatment inevitably leads to a swift decline in this age group. However, the authors are careful to note that their study focused on a specific population: women who were healthy enough to undergo treatment and who rarely received chemotherapy. The study does not prove that all older women will have the same experience, particularly those who are already frail or those who require more aggressive drug therapies. The observation period was also limited to one year, leaving open the question of what might happen over several years.
Ultimately, this research offers a reassuring perspective for doctors and patients navigating these difficult decisions. It indicates that for a significant portion of the elderly population, treating breast cancer does not have to come at the cost of their functional independence or cognitive health in the short term. The study highlights that with careful patient selection and appropriate treatment choices, it is possible to fight the disease without sacrificing the quality of life that defines the later years. While the need for longer-term studies remains, the evidence from this year-long observation provides a clear signal that the fear of inevitable, rapid decline following treatment may not be as universal as once thought.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.